Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer
PLOS One · 2025
DOI: 10.1371/journal.pone.0326056 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Sung-Chi Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Abstraction Esophageal cancer is a devastating disease. The cisplatin and 5-FU regimen is the most widely used concurrent chemoradiotherapy protocol for metastatic, unresectable advanced esophageal cancer in Asia. However, its effectiveness remains limited due to unsatisfactory outcomes. Therefore, we conducted a retrospective study to evaluate the efficacy and toxicity of Cisplatin + 5-FU combined with docetaxel, leucovorin, methotrexate, and epirubicin (CDFLME), a first-line multi-agent chemotherapy regimen used for the treatment of advanced esophageal cancer in Taiwan. We enrolled 94 patients in our study from January 2018 to June 2022. All patients were diagnosed with metastatic or unresectable advanced esophageal cancer. Among them, 81 patients received fluorouracil + cisplatin regimen serving as the control group, while 13 patients received the CDFLME combination regimen. Significant improvements were observed in the CDFLME group compared to the fluorouracil + cisplatin group in overall survival time, complete response rate, and disease control rate. No significant differences were noted in treatment-related deaths or grade 3–4 adverse events, except for grade 1–2 mucositis. Based on these findings, we conclude that the CDFLME regimen is a promising alternative treatment with relatively minor adverse events and is an effective protocol for patients with advanced esophageal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.
- Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan, ROC.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
ORCID-Profile: Sung-Chi Yu, Bing-Yen Wang
Zitieren
APA
Yu, S. C., Tong, S. S., Chen, Y. L., Cheng, Y. F., Lin, J. C., Cheng, C. Y., Huang, C. L., Hu, W. H., & Wang, B. Y. (2025). Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer. PLOS One. https://doi.org/10.1371/journal.pone.0326056
Vancouver
Yu SC, Tong SS, Chen YL, Cheng YF, Lin JC, Cheng CY, et al. Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer. PLOS One. 2025. doi:10.1371/journal.pone.0326056
BibTeX
@article{Yu2025,
author = {Yu, Sung-Chi and Tong, Shao-Syuan and Chen, Yi-Ling and Cheng, Ya-Fu and Lin, Jin-Ching and Cheng, Ching-Yuan and Huang, Chang-Lun and Hu, Wei-Heng and Wang, Bing-Yen},
title = {Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0326056}
}
EUVIMED